Emtricitabine/tenofovir disoproxil fumarate in HIV-1 pre-exposure prophylaxis: a guide to its once-daily use in the EU
| Autor: | Emma D. Deeks, Greg L. Plosker, Katherine A. Lyseng-Williamson |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty business.industry Human immunodeficiency virus (HIV) virus diseases Pharmacy Pharmacology medicine.disease_cause Emtricitabine 030112 virology Men who have sex with men Clinical trial 03 medical and health sciences Pre-exposure prophylaxis Regimen 0302 clinical medicine Pharmacotherapy Internal medicine medicine Pharmacology (medical) 030212 general & internal medicine business medicine.drug |
| Zdroj: | Drugs & Therapy Perspectives. 33:8-15 |
| ISSN: | 1179-1977 1172-0360 |
| DOI: | 10.1007/s40267-016-0363-9 |
| Popis: | The fixed-dose combination of emtricitabine/tenofovir disoproxil fumarate (tenofovir DF) [Truvada®] is approved in the EU for pre-exposure prophylaxis, in conjunction with safer sex practices, to reduce the risk of sexually-acquired HIV-1 infection in adults at high risk. Once-daily administration of emtricitabine/tenofovir DF was effective in preventing HIV-1 infection in clinical trials in high-risk populations, including men who have sex with men, heterosexual HIV-1-serodiscordant couples, and heterosexual men and women. As adherence to the regimen correlates with the risk of HIV-1 infection, it is important that patient adhere to pre-exposure prophylaxis. Pre-exposure prophylaxis with the combination was generally well tolerated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink